Post Reply
Posts: 11
Joined: Fri Jan 10, 2020 2:51 pm


Post by sen117 » Thu May 21, 2020 4:44 pm

It appears that this question requires some understanding of NF-κB signaling pathway. What is the take away from this mechanism? How would I have known that compound 2 itself will initiate the anti-apoptotic NF-kB signaling pathway when both comp 1&2 were administered simultaneously?
If there's a way to deduce it by figure analysis, could you please walk me through it? Thank you.
Posts: 609
Joined: Sat Mar 30, 2019 8:39 pm

Re: AAMC FL 4 CP 24

Post by NS_Tutor_Mathias » Fri May 22, 2020 9:39 pm

No information from outside the passage is required here.

The answer key is simply stating that if both compounds are administered simultaneously, the NF-kB pathway won't be inhibited in every cell yet by the time camptothecin reaches them and starts acting. Thereby, the aptoposis-inhibiting NF-kB pathway (again: we know this from the passage) will activate and reduce the effectiveness of the drug.

At it's heart, this is a very simple question: You are told that Compound 1 sensitizes to Compound 2, and whether administering them simultaneously or 1 and then 2 makes more sense. You are given the data in figure 2 and the description of the pathway and of compound 1 as a sensitizing agent to base your answer on. The mechanical details don't even matter, although they are present within the passage.
Post Reply